Literature DB >> 7671438

Cyclosporine A hepatotoxicity: effect of prolonged treatment with cyclosporine on biliary lipid secretion in the rat.

A I Galán1, E Fernández, D Morán, M E Muñoz, R Jiménez.   

Abstract

1. The effects of cyclosporine A (CyA) treatment on liver morphology, bile flow and biliary secretion of bile acid, cholesterol and phospholipid and some plasma biochemical indicators of liver function were examined. 2. Wistar rats were treated i.p. with 10 or 20 mg of CyA/kg per day for 1, 2, 3 or 4 weeks. 3. Treatment increased bile acid and bilirubin plasma concentration. Bile flow and biliary secretion of bile acid, cholesterol and phospholipid were reduced in CyA-treated animals. 4. All these effects of the drug appeared at 1 week after the start of treatment and were enhanced during prolonged treatment. Cyclosporine A-induced cholestasis was due to a decrease in both the bile acid-dependent and -independent fractions of bile flow. 5. The reduction in cholesterol and phospholipid biliary output may be secondary to the inhibition of the hepatobiliary flux of bile acid; however, perturbations in the removal of lipids from the canalicular membrane as well as intracanalicular interaction between CyA and lipid vesicles/micelles could also be involved.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7671438     DOI: 10.1111/j.1440-1681.1995.tb01991.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  8 in total

1.  Comparative study analyzing effects of sirolimus-cyclosporin and sirolimus-tacrolimus combinations on bile flow in the rat.

Authors:  M Deters; K Nolte; G Kirchner; K Resch; V Kaever
Journal:  Dig Dis Sci       Date:  2001-10       Impact factor: 3.199

2.  Effect of dietary lipids on hepatic Na+,K(+)-ATPase in cyclosporine A-treated rats: immunocytochemical analysis of alpha1 subunit by confocal laser scanning microscopy imaging.

Authors:  L Benkoël; F Chanussot; F Dodero; C de la Maisonneuve; R Lambert; J Brisse; A Chamlian
Journal:  Dig Dis Sci       Date:  1999-08       Impact factor: 3.199

3.  Role of S-adenosylmethionine on the hepatobiliary homeostasis of glutathione during cyclosporine A treatment.

Authors:  A I Galán; M E Muñoz; J Palomero; C Moreno; R Jiménez
Journal:  J Physiol Biochem       Date:  2000-09       Impact factor: 4.158

4.  Cyclosporine exacerbates ketamine toxicity in zebrafish: Mechanistic studies on drug-drug interaction.

Authors:  Bonnie L Robinson; Melanie Dumas; Syed F Ali; Merle G Paule; Qiang Gu; Jyotshna Kanungo
Journal:  J Appl Toxicol       Date:  2017-06-01       Impact factor: 3.446

5.  Sirolimus/cyclosporine/tacrolimus interactions on bile flow and biliary excretion of immunosuppressants in a subchronic bile fistula rat model.

Authors:  Michael Deters; Til Klabunde; Gabriele Kirchner; Klaus Resch; Volkhard Kaever
Journal:  Br J Pharmacol       Date:  2002-06       Impact factor: 8.739

Review 6.  Hepatic manifestations of non-steroidal inflammatory bowel disease therapy.

Authors:  Robert Hirten; Keith Sultan; Ashby Thomas; David E Bernstein
Journal:  World J Hepatol       Date:  2015-11-28

Review 7.  Cyclosporine A: Novel concepts in its role in drug-induced gingival overgrowth.

Authors:  Deepa Ponnaiyan; Visakan Jegadeesan
Journal:  Dent Res J (Isfahan)       Date:  2015 Nov-Dec

8.  Alport syndrome: significance of gingival biopsy in the initial diagnosis and periodontal evaluation after renal transplantation.

Authors:  Hilal Uslu Toygar; Okan Toygar; Esra Guzeldemir; Ulkem Cilasun; Ahmet Nacar; Nebil Bal
Journal:  J Appl Oral Sci       Date:  2009 Nov-Dec       Impact factor: 2.698

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.